MyFinsight
Home
Blog
About
Loss on debt
extinguishment, net
-$30,782K
Proceeds from issuance of
employee stock purchase...
$985K
(18.67%↑ Y/Y)
Proceeds from issuance of
warrants
$600K
Proceeds from exercise of
stock options
$549K
(-90.59%↓ Y/Y)
Stock-based compensation
$11,066K
(17.09%↑ Y/Y)
Accrued trade discounts
and rebates
$6,049K
(-28.37%↓ Y/Y)
Other
$4,979K
(356.37%↑ Y/Y)
Amortization of intangible
assets
$2,711K
(-49.99%↓ Y/Y)
Amortization of debt discount
and debt issuance...
$907K
(-45.49%↓ Y/Y)
Depreciation
$323K
(-49.53%↓ Y/Y)
Accounts payable
$286K
(177.93%↑ Y/Y)
Amortization of operating
right-of-use assets
$176K
(-28.46%↓ Y/Y)
Net cash provided by
(used in) operating...
$8,263K
(183.90%↑ Y/Y)
Net cash used in
financing activities
$1,943K
(188.52%↑ Y/Y)
Canceled cashflow
$49,016K
Canceled cashflow
$191K
Net increase
(decrease) in cash, cash...
$9,997K
(181.04%↑ Y/Y)
Canceled cashflow
$209K
Net loss
-$31,101K
(-178.98%↓ Y/Y)
Inventory
$9,502K
(-15.08%↓ Y/Y)
Prepaid expenses and
other current assets
$4,489K
(348.97%↑ Y/Y)
Trade accounts
receivable
$1,810K
(-85.67%↓ Y/Y)
Other accrued
liabilities
-$1,512K
(53.19%↑ Y/Y)
Operating lease
liabilities
-$477K
(35.71%↑ Y/Y)
Accrued returns reserve
-$125K
(-117.86%↓ Y/Y)
Repurchase of common stock
withheld for taxes
$191K
(-97.84%↓ Y/Y)
Net cash used in
investing activities
-$209K
(28.42%↑ Y/Y)
Capital expenditures
-$209K
(28.42%↑ Y/Y)
Back
Back
Cash Flow
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)
source: myfinsight.com